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Introduction
Approximately 12 years and over 1 billion dollars are required to develop one new medicine from the earliest stages of discovery to approval. Only a tiny percentage of the compounds entering the drug discovery pipeline reach the market. High-throughput screening (HTS) is one of the primary pharmaceutical methods for identifying lead compounds, but it has a high false positive rate. Candidates are not routinely translated into new drugs. This leads to the delay or failure of drug discovery projects. 1 The reasons for this include unclear target biology, poor drug-like properties, low potency or selectivity, lack of efficacy, unexpected toxicity, etc.
Failures in the later stages are extremely costly. It is therefore of paramount importance to identify early-on lead compounds that interact with the target in a biologically relevant mechanism without inducing adverse modes of action.
In recent years, more dynamic models of molecular recognition have superseded Emil
Fischer's rigid lock-and-key binding paradigm. The two major paradigms are now the induced-4 fit and the conformational selection models. 2 It is now increasingly clear that both mechanisms contribute to molecular recognition, which requires a dynamic description over timescales spanning several orders of magnitude to be fully understood. This presents a fundamental theoretical and computational challenge. 3 Molecular dynamics (MD) simulations have greatly contributed to understanding molecular recognition phenomena as a fully dynamical process. But they are limited by the timescales that can be routinely sampled. Very recently, with the introduction of special-purpose machines such as Anton, 4 the porting of MD codes to GPUs, 5 and the evolution of parallel codes, 6 ,7 the timescales accessible by fully atomistic MD have increased enormously. Simulations lasting up to a few ms (corresponding to 10 12 time-steps) are now possible. However, drug-like molecules with long residence times (more than an hour) are common, and their unbinding cannot be observed by conventional MD calculations even when specialized hardware is used. This wellrecognized limitation of MD is not limited to ligand binding and has led to the development of many innovative algorithms to enhance the sampling of the high-in-free-energy states and the rare events that allow the crossing of very high-free-energy barriers. transition path sampling, 15 and their many combinations and derivatives are among the most widely used methods to enhance conformational sampling. Of the enhanced sampling methods that fully explore the binding mechanism, metadynamics, 11 especially in the well-tempered formulation, 16 has emerged as a powerful approach for accelerating rare events and computing multidimensional free energy surfaces (FESs). Metadynamics is a family of methods that flatten the FES as a function of a set of collective variables (CVs), by introducing a bias that prevents 5 the system from being trapped in local free energy minima ( Figure 1 ). It shares many similarities with other CV-based algorithms, [17] [18] [19] [20] [21] [22] and it has significantly evolved since its introduction. In contrast to other approaches, the reconstruction of the FES can be easily done in more than 2 dimensions and does not require an additional step (such as WHAM 23 ). It has been recently proved under general circumstances that well-tempered metadynamics provides an unbiased estimate of the free energy of the system projected onto predefined CVs, albeit the convergence time depends critically on how optimal are the CVs. 24 By "optimal CVs", one generally means a small set (2-4) of variables, function of the atomic positions (e.g. distance), whose combination provide a good description of the reaction coordinate and is able to clearly distinguish between different free energy minima, kinetic basins and binding pathways.
An open source plug-in implementation of metadynamics (PLUMED) 25 working with many widely-used MD codes, as well as native implementations for NAMD, Desmond and other codes are available. In drug discovery, it can provide the location of cryptic pockets, an estimate of the binding free energy, including conformational changes of the target, as well as quantitative information on the metastable minima and transition states, which can be used to optimize the underlying ligand binding and unbinding kinetics.
In this Account, we review recent applications of metadynamics and compare it to other enhanced sampling approaches in drug-discovery-related endeavors, providing some perspective on the advantages, disadvantages, and practical applicability of these methodologies in academic and industrial settings.
Protein-ligand binding and unbinding
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MD simulations have contributed in major ways to our understanding of molecular recognition and consequently to drug design. HIV-integrase inhibitors are a classic example. MD simulations revealed a previously unknown "trench", which was invisible to X-ray crystallography and traditional docking methods. 26 This suggested a way of designing stronger inhibitors binding to both the catalytic site and the newly discovered trench. A few notable examples in the literature deal with the long time span required for a binding process to occur spontaneously, by running MD simulations lasting a few microseconds. [27] [28] [29] However, the timescale problem still hampers an extensive application of fully atomistic MD in drug design. In the context of accelerated sampling methods, metadynamics-based approaches have been successfully applied to drug design, particularly when major conformational motions play a role prior to and upon a drug binding to a target.
The first application of metadynamics to ligand-binding was carried out by Gervasio et al., who studied four different complexes. 30 The correct geometry corresponded to the deepest free energy minimum in all the cases, demonstrating the ability of the method to predict the correct binding mode. In the case of the trypsin-benzamidine complex, the algorithm was extensively compared to 2D umbrella sampling and was found to provide the free energy reconstruction in less time. The experimental binding energy was correctly predicted. In the case of the CDK2/staurosporine complex, albeit the correct docking pose was predicted, the computed binding free energy was significantly overestimated (20 kcal/mol vs. 11 kcal/mol). This was due to: a fast filling time (a total of only 8 ns), an inaccurate ligand force-field, the lack of a correction for the standard volume of the unbound state and sub-optimal CVs. Nowadays, thanks to the significant increase in available computational resources and the introduction of the welltempered variant of metadynamics, the bias is added at a much slower rate and the FES is usually 7 filled in hundreds if not thousands of ns. The ligand force-field still remains a major concern.
While there has been a significant progress in the accuracy of protein force-fields, [31] [32] generallyavailable ligand force-fields lag behind, and despite recent progress, 33 careful re-parameterization of ligands based on ab-initio calculations is strongly advised. As for the CVs, major progress has been achieved in the design of optimal coordinates. In Gervasio's et al. paper 30 , the choice of geometry-based CVs (distance and angle) was guided by three requirements: i) a general applicability in molecular recognition, ii) the need to distinguish all the minima along the reaction coordinate, and iii) the need to keep the number of CVs low. The latter requirement is due to the fact that the time needed to "fill the minima" (see Figure 1 ) in principle increases exponentially with the number of the CVs.
The need to choose a set of optimal CVs is the main drawback of metadynamics and other CVbased methods. In a subsequent study, Masetti et al. systematically explored different combinations of CVs and faster approaches to converge the free energy estimation. 34 A combination of docking, cluster analysis, 35 and metadynamics limited to exploring the internal cavity up to the transition state (coarse-metadynamics) improved scoring in conventional structure-based endeavors. To date coarse-metadynamics together with optimal CVs is still one of the best ways to use metadynamics to rank different ligands binding to the same target.
However, to compute the relative free energy of a set of similar compounds (having a similar binding pose), end-point methods, i.e. methods that compute the difference of free energy between the bound and the unbound state, such as thermodynamic integration (TI) are in most cases more efficient than methods that compute the free energy along a physical association pathway.
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Another early application was Branduardi et al.'s study of the binding mechanism of the tetramethylammonium (TMA) ion by human acetylcholinesterase (AChE). 36 The AChE peripheral anionic site (PAS), located at the entrance of the gorge, is solvent-exposed, therefore plain MD simulations are able to identify stable docking conformations. 37 However, enhanced sampling approaches are needed to explore binding into the deep internal gorge. 38 Metadynamics was run with two CVs, the distance between ligand and the binding pocket, along with a new CV describing the cation-π interaction, leading to a well-converged free energy reconstruction.
Cation-π interactions were shown to play a fundamental role in both the initial recognition between TMA and the PAS, and the gorge binding mechanism. Notably, the cation-π CV must be included to obtain a converged FES.
Beside protein-ligand systems, metadynamics has also been applied to study the association mechanism of molecules binding to DNA and RNA, e.g. the interaction of ligands with DNA Gquadruplexes, 39 and the unbinding of the anticancer drug distamycin from the DNA minor groove. 40 Other methods, such as steered MD, have also been successfully used to characterize binding poses and to drive the selection of biologically active compounds. Colizzi et al. have exploited docking and steered MD to discern between active and inactive antimalarial ligands. 41 By modeling the force that is required to pulling inhibitors out of their binding pocket complex, it was possible to separate strong binders from weak ones. Strongly bound inhibitors gave profiles with higher peak forces than weakly bound inhibitors, which gave a flat profile (Figure 2 ).
Compared to metadynamics, in steered MD the choice of the CV is less crucial, allowing a quick exploration of many unbinding events. However, it is less efficient in computing fully converged free energy profiles.
Reconstructing the free energy landscapes
As discussed above, selecting a limited number of optimal CVs is a crucial step in metadynamics simulations to obtain a converged free energy landscape. The most commonly used CVs in drug-binding simulations are geometry-based and involve a combination of distances, contacts, angles, and dihedrals. In complex cases, several attempts might be needed to find a proper combination of variables (sub-optimal set of variables are easily recognized as the reconstructed FES shows hysteresis as a function of time). In analogy to similar strategies used with umbrella-sampling, 43 various restraining potentials have been used. An interesting choice is to use a reverse funnel-shaped potential that limits the space available to the ligand once it has undocked. 44 Funnel metadynamics was used to revisit some of the systems previously studied with geometrical CVs or PCVs, including the trypsinbenzamidine complex and the binding of the drug SC-558 to cyclooxygenase 2 (COX-2, see below). Thanks to the restraining potential, the unbound state can be thoroughly sampled leading to a faster convergence of the energy landscape.
A perhaps more elegant solution is the use of PCVs that describe the position of the system in the configuration space relative to an optimal exit path, in terms of progression along the path and distance from the path itself. PCVs are able to describe complex association pathways including target conformational changes and to restrain the sampling of the unbound state, improving convergence considerably. In the last few years, the PCV approach has been successfully used to study complex conformational changes and drug-target binding. 45, 46 Fidelak et al. 47 used PCVs to study the binding of a congeneric series of ligands to CDK2. Identifying the correct order of activity of the compounds was non-trivial, due to the lack of interaction between the protein and the aryl-pyrimidine substituents differentiating the homologous inhibitors. Using well-tempered metadynamics and PCV, the authors converged a full association free energy profile in remarkable agreement with the experimental binding energies. They also fully characterized the association mechanism. In a subsequent work, Saladino et al. 48 studied a wellknown series of p38 inhibitors, frequently used to assess the performances of scoring algorithms, whose activity cannot be easily guessed. The authors moved a step further towards making metadynamics suitable for a pharmaceutical workflow and used a semi-automatic setup. With a similar intent, Mason and coworkers 49 at Heptares Therapeutics designed the MetaScore routine, a fast metadynamics-based protocol, used to predict the effect of different mutations on the binding of antagonists to the adenosine A 2A receptor. The MetaScore scoring function is based on a two-step semi-automatic protocol that uses several adiabatic biased MD simulations to obtain an initial association path and construct PCVs, followed by short well-tempered metadynamics runs to calculate the full binding free energy profile. Using this approach, the authors predicted the correct binding energy changes resulting from active site mutations. PCV were also used by Provasi et al. 50 to access the free energy of binding of several ligands to another G-proteincoupled receptor, the β2-adrenergic receptor.
When the binding is accompanied by large-scale conformational changes, the choice of CVs can be daunting. In such cases, Parallel Tempering Metadynamics (PT-MetaD) 51 , an approach that couples metadynamics with a replica exchange algorithms, can enhance the sampling of hidden (slow) degrees of freedom and greatly improve convergence. It has been used to compute the FES associated with the inactive-to-active conformational changes of the cancer target epidermal growth factor receptor. 46 PT-metaD, albeit being a very expensive approach, is the method of choice when large-scale conformational changes are involved and a converged FES is required. Finally, the number of CVs is not an issue in Bias Exchange Metadynamics (BEMD) 52 and Reconnaissance Metadynamics. 53 The latter uses a self-learning algorithm that clusters the visited conformations on-the-fly and bias along a one-dimensional clustering-based CV. These approaches have been effectively used to explore very complex molecular recognition events and are very beneficial when little information is known about the association mechanism and the location of the binding cavity. Both methods, however, require extra efforts to reconstruct the free energy landscapes, and thus are best used as a means to explore different binding mechanisms.
Pharmaceutical applications
Metadynamics was recently used to understand the differences in the binding mechanisms of a non-steroidal anti-inflammatory ligand (SC-558) to COX-1 and COX-2 isoforms. 54 Selective inhibition of COX isoforms has been actively sought, leading to new generations of widely used COX-2 selective drugs. Recently, significant effort has been made to understand the selectivity and the differences in the binding mechanism of inhibitors to COX-1 and COX-2. In this study, metadynamics and the PCV method 42 were used to describe the (un)binding of a ligand and the associated conformational change of three α-helices that form a narrow gate through which the ligand exits from the protein. In the case of the COX-2 isoform, two separate and almost equally favorable minima in the FES are found (Figure 3 ), while only one deep minimum was found in COX-1. The existence of two binding modes in COX-2 only explain both the selectivity of the ligand and, interestingly, the increased residence time of the ligand in COX-2 relative to COX-1.
A similar approach was used to study the aspartate uptake and internal release mechanism through a membrane protein, namely the amino acid transporter from Pyrococcus horikoshii. 55 The transport of the substrate is assisted by the cotransport of Na + ions and is mediated by the concerted motion of the transmembrane domain and the two hairpins (HP1 and HP2) that regulate access to either side of the membrane. In addition, it is known that this transporter may assume at least four different conformational states, which further challenges the study of the substrate translocation across the channel. Grazioso et al. used PCV to enhance the highly cooperative transition upon substrate binding and transport across the membrane. 55 The authors thus described the complete opening mechanism involving a large-scale motion of HP2, which allowed substrate uptake, with a similar role played by HP1 in the inward release mechanism ( Figure 4) .
As a final case study, PT-metaD with PCVs and BEMD have been used to study the mode of action of a novel inhibitor of the fibroblast growth factor receptor (FGFR). 56 FGFRs are tyrosine kinase receptors whose signaling pathway is involved in cell growth, proliferation, and survival. 
Binding and unbinding kinetics estimation
Obtaining reliable estimates of the kinetics constants associated with ligand binding is an ambitious goal of modern computational drug discovery, with significant potential benefits in the lead discovery and the lead optimization steps of the drug discovery process. 57 The possibility of reconstructing and estimating the binding free energy along physical association pathways provides quantitative information on the metastable minima and transition states. These can then be used to optimize the underlying ligand binding kinetics to achieve therapeutically safe and differentiated responses. Researchers increasingly recognize the importance of ligand target residence time in fine-tuning in vivo efficacy and toxicology. 58 Knowledge of the metastable 14 states and the residues involved in a ligand's access to the binding cavity could lead to the design of novel drugs that are more potent and selective for therapeutically relevant targets.
Metadynamics in the bias-exchange variant was used by Pietrucci et al. to investigate the key events in the binding of the p2-NC peptide to the Human Immunodeficiency Virus type-1
Protease (HIV1-1 PR) . 59 The free energy was computed as a function of seven CVs, in order to characterize the physical interactions that might play a role in stabilizing the complex and the transition states. From the BE-META trajectories, a thermodynamic and kinetic model of the binding process was constructed based on the weighted-histogram approach ( Figure 5 ).
Remarkably, mutation of residues along the access region identified by BE caused resistance to some FDA-approved peptidomimetic drugs, providing an experimental validation. Individual water molecules at the interface between ligand and enzyme played a pivotal role throughout the binding process and a CV describing "interfacial water" was needed to discriminate different intermediate states.
In absence of large barriers to binding/unbinding, Markov state models (MSM) 60 Introducing a new recursive expression for the transmission coefficient, the authors designed a robust approach with very general applicability and high accuracy.
Perspectives
In Table 1 and Figure 6 , we summarize the suggested metadynamics-based approach to use in drug discovery. In particular we address the cases of cryptic binding sites, scoring different ligands binding to the same target, full free energy reconstruction with or without large conformational changes and binding kinetics. As we have detailed in the preceding sections, metadynamics-based approaches are not always the most effective choice. In Figure 7 , we report on the major strengths and weaknesses of these methods. One of major drawbacks of metadynamics is still related to the choice of CVs, which can compromise a proper reconstruction of the FES associated to the process under investigation. In this scenario, some recent and on-going developments, particularly suited to drug discovery, are the use of nonlinear dimensionality reduction techniques to automatically find the optimal CVs, new CVs to find and score cryptic binding sites and, going beyond the current methods, a new variational approach to construct an optimal bias potential and reconstruct the FES. 63 All these evolutions will contribute to a further expansion of metadynamics approaches to drug discovery, widening the plethora of computational tools utilized to estimate binding and unbinding free energy and kinetics, and eventually accelerating the discovery of novel bioactive compounds. 
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